Combating Ovarian Cancer Using Stem Cell-Engineered Off-The-Shelf CAR-iNKT Cells
Grant Award Details
Grant Type:
Grant Number:
DISC2-13505
Investigator(s):
Disease Focus:
Human Stem Cell Use:
Award Value:
$1,402,662
Status:
Closed
Progress Reports
Reporting Period:
Year 2
Grant Application Details
Application Title:
Combating Ovarian Cancer Using Stem Cell-Engineered Off-The-Shelf CAR-iNKT Cells
Public Abstract:
Research Objective
HSC-engineered allogeneic mesothelin-targeting CAR-iNKT (AlloMCAR-iNKT) cells
Impact
treatment of ovarian cancer
Major Proposed Activities
HSC-engineered allogeneic mesothelin-targeting CAR-iNKT (AlloMCAR-iNKT) cells
Impact
treatment of ovarian cancer
Major Proposed Activities
- Milestone 1. Production of the AlloMCAR-iNKT cells
- Milestone 2. Characterization of the AlloMCAR-iNKT cells
- Milestone 3. Delivery of the new therapeutic candidate
Statement of Benefit to California:
Ovarian cancer (OC) is the leading cause of death among women with gynecological malignancies. In the USA, California is the state with the highest incidences and deaths of ovarian cancer. In 2021, it is estimated that 2,550 women will be diagnosed with OC and 1,640 women will die from this disease at California. Therefore, novel therapies are urgently needed. The proposed project can potentially lead to a novel off-the-shelf cell therapy for ovarian cancer and save lives
Publications
- Cell Stem Cell (2023): Advancing cell-based cancer immunotherapy through stem cell engineering. (PubMed: 36948187)
- Trends Pharmacol Sci (2024): Frontiers in CAR-T cell therapy for autoimmune diseases. (PubMed: 39147651)
- iScience (2023): Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design. (PubMed: 37810241)
